COLLABORATIVE ARRANGEMENTS (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Information related to collaborative arrangements
Revenue from collaborative arrangements	$ 439,000	$ 1,430,000	$ 3,110,000	$ 129,960,000
Total reduction to R&D expense	2,153,000	40,000	6,106,000	116,000
GSK
Information related to collaborative arrangements
Revenue from collaborative arrangements	415,000	1,430,000	3,059,000	4,291,000
Total reduction to R&D expense	181,000	40,000	517,000	116,000
Astellas
Information related to collaborative arrangements
Revenue from collaborative arrangements				125,669,000
Other
Information related to collaborative arrangements
Revenue from collaborative arrangements	24,000		51,000
Merck
Information related to collaborative arrangements
Total reduction to R&D expense	1,501,000		4,579,000
Alfa Wassermann
Information related to collaborative arrangements
Total reduction to R&D expense	471,000		924,000
R-Pharm
Information related to collaborative arrangements
Total reduction to R&D expense			$ 86,000